Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cobalamin, commonly known as Vitamin B12, is a water-soluble vitamin being investigated as an adjuvant therapy for drug-induced movement disorders by the Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara. The drug is specifically being evaluated for its ability to treat syndromes such as tardive dyskinesia, dystonia, and parkinsonism in patients receiving antipsychotic medications for schizophrenia, schizoaffective disorder, or bipolar disorder. The therapeutic rationale is based on cobalamin's antioxidant properties, which may counteract the oxidative stress and free radical generation resulting from dopamine metabolism and chronic D2 receptor blockade in the striatum. In clinical trials, it is administered as an oral tablet at a dosage of 2mg daily.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cobalamin.